# Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

Source: https://onco.cc/trials/nct06514534/  
OnCo record `nct06514534` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Asciminib in chronic myeloid leukaemia, run by Novartis Pharmaceuticals, now recruiting.

## Summary

Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. is a phase 2 interventional study registered as NCT06514534 by Novartis Pharmaceuticals, with 20 participants planned, started 2025-02-18 and due to reach its primary completion in 2029-02-17. Interventions recorded: ABL001/Asciminib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06514534
- Phase: 2
- Setting: A Phase II, Multi-center, Prospective, Open-label Study of Asciminib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or Accelerated Phase (CML-AP) With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT06514534: https://clinicaltrials.gov/study/NCT06514534

## Connected records

- cancers: [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/)
- drugs: [Asciminib](https://onco.cc/drugs/asciminib/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/)

---
JSON: https://onco.cc/api/v1/entities/nct06514534.json